NASDAQ:KZIA
Kazia Therapeutics Limited Stock News
$0.282
-0.0121 (-4.11%)
At Close: May 17, 2024
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
02:30pm, Monday, 22'nd Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of p
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
04:39am, Monday, 22'nd Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of p
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
02:30pm, Monday, 01'st Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of
Even if it's not a huge purchase, we think it was good to see that Iain Ross, the Independent Chairman of the Board of...
Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?
04:49am, Monday, 25'th May 2020
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
NLY, NRZ among premarket gainers
01:20pm, Wednesday, 08'th Apr 2020
Ellington Financial (NYSE:EFC) +54% as book value holds up.New York Mortgage Trust (NASDAQ:NYMT) +39% on updating on financing, portfolio.Myomo (NYSEMKT:MYO) +26% on accelerating growth in pipeline
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
12:00pm, Tuesday, 07'th Apr 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (forme
Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?
09:34pm, Monday, 24'th Feb 2020
James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...
Edison issues ADR update on Kazia Therapeutics (KZIA)
12:55pm, Monday, 13'th Jan 2020
LONDON, UK / ACCESSWIRE / January 13, 2020 / Kazia Therapeutics (NASDAQ:KZIA) has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
03:00pm, Wednesday, 11'th Dec 2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE,
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
01:45pm, Monday, 02'nd Dec 2019
LONDON, UK / ACCESSWIRE / December 2, 2019 / Kazia Therapeutics (NASDAQ:KZIA) has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data a
If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
10:12pm, Thursday, 28'th Nov 2019
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
03:00pm, Monday, 25'th Nov 2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 i
Kazia Raises A$4.0 Million to Progress R&D Programs
02:16am, Monday, 28'th Oct 2019
NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to i
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
12:00pm, Friday, 13'th Sep 2019
SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019
